Welcome to our dedicated page for Abeona Therapeut SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Abeona Therapeutics Inc. (ABEO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Abeona is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, and its filings offer detailed insight into the business, including the commercialization of ZEVASKYN® (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa (RDEB) and the development of AAV-based gene therapies for ophthalmic conditions.
Investors can review current reports on Form 8-K, where Abeona reports material events such as quarterly financial results, operational updates on ZEVASKYN manufacturing and launch activities, and transactions like the sale of a Rare Pediatric Disease Priority Review Voucher awarded upon FDA approval of ZEVASKYN. These filings also confirm that Abeona’s common stock, with a par value of $0.01 per share, trades on The Nasdaq Capital Market under the symbol ABEO.
In addition to 8-Ks, users can access annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for information on Abeona’s research and development spending, selling, general and administrative expenses related to the ZEVASKYN launch, cash and investment balances, debt obligations, and risk factor disclosures relevant to its gene therapy programs and manufacturing operations.
Stock Titan enhances these documents with AI-powered summaries that help explain key sections of lengthy filings, such as revenue descriptions, cost structures, and updates on regulatory interactions. The platform also surfaces insider transaction reports on Form 4 when filed, enabling users to track equity awards and other changes in beneficial ownership by Abeona’s officers and directors.
By combining real-time EDGAR updates with AI-generated highlights, this ABEO filings page is designed to make Abeona’s complex biopharmaceutical and gene therapy disclosures more accessible to investors, analysts, and other interested readers.
Abeona Therapeutics Inc. is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders to be held June 12, 2026 for routine corporate governance votes and several governance and compensation proposals. Key items include election of three Class 1 directors, an advisory say-on-pay vote, ratification of Deloitte & Touche LLP, approval to increase the 2023 Equity Incentive Plan reserve from 8,400,000 to 11,500,000 shares, and an amendment to remove the advance notice provision for director nominations.
The record date for voting is April 15, 2026; shares outstanding were 56,882,523 as of that date. The Board recommends FOR each nominee and each proposal noted above. Voting instructions, proxy-return methods, and virtual meeting access are provided in the proxy materials.
Goldan Keith A. reported acquisition or exercise transactions in this Form 4 filing.
Abeona Therapeutics Inc. director Keith A. Goldan received a grant of restricted common stock. He was awarded 32,751 shares of common stock at a stated price of $0.00 per share, increasing his directly held position to 32,751 shares after the transaction.
According to the filing, all of this restricted stock will vest on April 1, 2027, meaning the shares are subject to service-based conditions until that date and are compensation-related rather than an open-market purchase.
Abeona Therapeutics Inc. insider data show that Keith A. Goldan is a reporting person serving as a director. The Form 3 insider filing excerpt lists no buy, sell, acquisition, or disposition transactions and shows no derivative positions or holding entries in the provided data.
Abeona Therapeutics Inc. reported that its Board of Directors expanded from nine to ten members and appointed Keith A. Goldan as a Class 1 independent director, effective April 1, 2026, with a term expiring at the 2026 annual stockholders’ meeting. He was also named Chair of the Audit Committee, and the Board determined he meets Nasdaq independence standards. Abeona will pay him an annual cash Board fee of $50,000 and a one-time $150,000 restricted stock award that vests over one year, with eligibility for the Board’s next regular equity grant in 2027.
Abeona Therapeutics ownership disclosure: Funicular Funds, LP, Cable Car Capital, LP and Jacob Ma-Weaver each report beneficial ownership of 3,007,329 shares of Abeona Therapeutics common stock, representing 5.3% of the class. The calculation references 57,049,023 shares outstanding as of March 17, 2026. The filings list sole voting and sole dispositive power over the reported shares and provide the filers' business address in San Francisco.
Abeona Therapeutics Inc. CEO Vishwas Seshadri sold 29,985 shares of common stock in an open-market transaction. The sale occurred on March 31, 2026 at a weighted average price of $4.3849 per share, with individual trades between $4.31 and $4.43.
After the transaction, Seshadri directly held 1,430,423 shares of Abeona common stock. The filing states that the sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on September 17, 2024, indicating it was scheduled in advance.
ABEO filed a Form 144 notifying a proposed sale of 29,985 shares of Common Stock. The filing identifies these shares as Restricted Stock dated 06/05/2024 and notes a prior sale of 69,832 shares on 01/22/2026 for $372,267.00.
The notice lists the broker Stifel Nicolaus & Company Inc and indicates Nasdaq as the exchange; timing and proceeds distribution beyond the amounts shown are not detailed in the excerpt.
Abeona Therapeutics Inc. ownership filing reports that Daniel Kaufman beneficially owns 2,943,629 shares of Common Stock, representing 5.16% of the class. The filing lists Kaufman’s sole voting and dispositive power over these shares.
The Schedule 13G is signed by Daniel Kaufman on 03/27/2026 and discloses his address and CUSIP 00289Y206.
Abeona Therapeutics Inc ownership update: The Vanguard Group filed an amendment reporting zero shares beneficially owned of Abeona common stock following an internal realignment. The filing states Vanguard's subsidiaries will report separately in reliance on SEC Release No. 34-39538, and Vanguard no longer is deemed to beneficially own the securities reported by those subsidiaries.
Abeona Therapeutics Inc. reported that its Board approved Third Amended and Restated Bylaws, effective March 16, 2026, fully replacing bylaws adopted in July 2024. The revisions clarify how annual and special shareholder meetings can be called, postponed, rescheduled, or canceled, and expressly allow virtual meetings under Delaware law.
The bylaws eliminate the requirement to make a shareholder list available at meetings, add rules for attending meetings via remote communication, and raise the quorum requirement from one-third to 50% of shares entitled to vote. They also strengthen procedural and disclosure requirements for shareholder proposals and director nominations, including conditions for using the SEC’s universal proxy rules.